Non-Small Cell Lung Cancer Market Company Profiles and Key Players Analysis by 2028

Comments · 134 Views

The Non-Small Cell Lung Cancer size is forecast to reach USD 11.87 Billion by 2028, registering a CAGR of 6.2% over the forecast period, according to a new report by Reports and Data.

The Non-Small Cell Lung Cancer size is forecast to reach USD 11.87 Billion by 2028, registering a CAGR of 6.2% over the forecast period, according to a new report by Reports and Data. Major factors driving market revenue growth is the introduction of immune checkpoint inhibitors (ICIs) into the first-line context. Non small cell lung cancer accounts for 80 percent to 85 percent of all lung cancer cases across the world, and this high proportion has prompted the majority of market leaders to focus on constant innovation of new therapies and improving the efficacy of existing medicines. The market growth is also owing to lung cancer’s reputation as one of the most common malignancies, contributing to a considerable number of deaths globally. The expansion of the non small cell lung cancer market is further aided by an increase in the frequency of diagnosis of non small cell lung cancer and increased awareness about the disease in developed and emerging countries. This, combined with increased spending by leading companies in research and development operations, as well as the inclusion of non-small cell cancer therapies in major market participants’ pipelines, is fueling global market expansion.

Top Companies Profiled in the Report Include:

Tarceva,

Avastin,

Gemzar,

Alimta,

Taxotere,

AstraZeneca,

Roche,

Merck KGa,

Nlyte,

Panduit Corp.

Market Overview:

The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop medications to cater to the growing unmet clinical demand on a global level. Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past. In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities. Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1475

The report has gather vital information about recent mergers and acquisitions, joint ventures, collaborations, partnerships, brand promotions, RD activities, and government and corporate deals, among others through extensive primary and secondary research. The report also offers detailed analysis of each competitor along with their financial standing, global market position, product portfolio, manufacturing and production capacity, and business expansion plans.

The report offers a comprehensive overview of the regional bifurcation of the market with respect to market share, market size, revenue growth, import/export, production and consumption patterns, macro and micro economic growth factors, regulatory framework, investment and funding opportunities, and presence of key players in each region including North America, Asia Pacific, Latin America, Europe, and Middle East Africa. The report offers a country-wise analysis to further discuss the revenue growth and lucrative growth opportunities for the Non-Small Cell Lung Cancer market in these key regions.

Country-wise regional analysis covers:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa

Additionally, the report consists a detailed analysis of the segmentation of the Non-Small Cell Lung Cancer market based on product types and end-use/application offered in the Non-Small Cell Lung Cancer market.

Histology Outlook (Revenue, USD Billion; 2018 – 2028)

  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Adenocarcinoma

Treatment Outlook (Revenue, USD Billion; 2018 – 2028)

  • Surgery
  • Radiation
  • Chemotherapy
  • Targeted Therapy Drugs

Drug Class Outlook (Revenue, USD Billion; 2018 – 2028)

  • Angiogenesis Inhibitor
  • Epidermal Growth Factor Receptor Blocker
  • Kinase Inhibitor
  • Microtubule Stabilizer
  • Folate Antimetabolites
  • PD-1/ PD-L1 Inhibitor

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Comments